{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:24:42Z","timestamp":1787739882530,"version":"build-2784847793"},"reference-count":157,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment-related adverse events are one of the leading barriers to tuberculosis treatment completion but have not been the focus of late-phase clinical trials. We performed a scoping review to identify interventions to improve the safety and tolerability of rifampin-susceptible tuberculosis. Our objective was to determine what interventions have been evaluated to prevent or manage adverse events, as well as what research is underway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We searched Embase, PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science from 1970 to December 2024 using a broad set of terms regarding adverse events, as well as citation searches to identify additional studies in topic areas that were not well-represented in the initial title search. To identify research in progress we searched Clintrials.gov, Cochrane reviews, and International Clinical Trials Registry Platform for trials reported to be active between January 2015 to April 2025. Of 7314 titles reviewed, 119 papers were available and eligible for this scoping review: 37 (31%) evaluated changes in the tuberculosis treatment regimen, 55 (46%) evaluated other interventions to prevent adverse events, and 27 (23%) evaluated treatment of adverse events. Only 7 studies reported enrollment of children\u2009&lt;\u200912 years old. Of the 49 clinical trials, 20 (41%) had sample sizes\u2009&lt;\u200950 participants\/arm. Notable gaps in research in this field: uncertainty about the safety of pyrazinamide, lack of research on prevention and management of nausea\/vomiting, uncertainty about the impact of hepatoprotectants, and lack of inclusion of children. Of the 8 study proposals that appear to be in progress, five were for a single topic: isoniazid dosing based on N-actyltransferase-2 status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There has been considerable research on improving the safety and tolerability of tuberculosis treatment, but its impact is limited by under-powered studies, the lack of inclusion of key subgroups, and important gaps in the research portfolio (uncertainties about the safety of pyrazinamide and the efficacy of hepatoprotectants, lack of research on ways to manage and prevent treatment-related nausea). It is concerning that the research pipeline for interventions to improve safety and tolerability appears to be quite limited Our review has identified promising interventions that may make treatment better tolerated, and hence, more effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0339354","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T18:34:55Z","timestamp":1766774095000},"page":"e0339354","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["A scoping review of interventions to prevent and treat adverse events during treatment of rifampin-susceptible tuberculosis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-1825","authenticated-orcid":true,"given":"William J.","family":"Burman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-6173","authenticated-orcid":true,"given":"M. Florencia","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7494-2098","authenticated-orcid":true,"given":"David","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8879-4989","authenticated-orcid":true,"given":"James","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"1","key":"pone.0339354.ref001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12879-018-3230-6","article-title":"Toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"18","author":"CD Tweed","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"8","key":"pone.0339354.ref002","first-page":"868","article-title":"Adverse drug reactions associated with first-line anti-tuberculosis drug regimens","volume":"11","author":"F Marra","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0339354.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019566","article-title":"Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study","volume":"6","author":"N Lorent","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"pone.0339354.ref004","article-title":"Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study","volume":"8","author":"X Lv","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"pone.0339354.ref005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bcp.15908","article-title":"No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review","volume":"90","author":"EG Dixon","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pone.0339354.ref006","article-title":"Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: a systematic review and meta-analysis","volume":"8","author":"AL Oh","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"7","key":"pone.0339354.ref007","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/bcp.15515","article-title":"Examining nonadherence in the treatment of tuberculosis: The patterns that lead to failure","volume":"89","author":"WS Fox","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pone.0339354.ref008","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/cid\/ciac867","article-title":"Adverse events associated with treatment for pan-susceptible tuberculosis in San Francisco","volume":"76","author":"JK Louie","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0339354.ref009","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"BS Kwon","year":"2020","journal-title":"PLoS One"},{"key":"pone.0339354.ref010","doi-asserted-by":"crossref","first-page":"3974651","DOI":"10.1155\/2017\/3974651","article-title":"Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014","volume":"2017","author":"MA Cardoso","year":"2017","journal-title":"Biomed Res Int"},{"issue":"7","key":"pone.0339354.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China","volume":"6","author":"P Shang","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"pone.0339354.ref012","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"RAM Breen","year":"2006","journal-title":"Thorax"},{"key":"pone.0339354.ref013","doi-asserted-by":"crossref","first-page":"7273935","DOI":"10.1155\/2016\/7273935","article-title":"Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study","volume":"2016","author":"AN Siddiqui","year":"2016","journal-title":"Biomed Res Int"},{"key":"pone.0339354.ref014","doi-asserted-by":"crossref","first-page":"444","DOI":"10.12659\/MSM.890012","article-title":"Alcoholism and other socio-demographic risk factors for adverse TB-drug reactions and unsuccessful tuberculosis treatment - data from ten years\u2019 observation at the Regional Centre of Pulmonology, Bydgoszcz, Poland","volume":"20","author":"G Przybylski","year":"2014","journal-title":"Med Sci Monit"},{"key":"pone.0339354.ref015","article-title":"Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review","author":"W Burman","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0339354.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004438","article-title":"Research on the treatment of rifampin-susceptible tuberculosis-Time for a new approach","volume":"21","author":"W Burman","year":"2024","journal-title":"PLoS Med"},{"key":"pone.0339354.ref017","article-title":"JBI Manual for Evidence Synthesis - Scoping Reviews","author":"MDJ Peters","year":"2024"},{"issue":"7","key":"pone.0339354.ref018","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"pone.0339354.ref019","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078384","article-title":"Guidance on terminology, application, and reporting of citation searching: the TARCiS statement","volume":"385","author":"J Hirt","year":"2024","journal-title":"BMJ"},{"issue":"7","key":"pone.0339354.ref020","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01567-09","article-title":"Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used","volume":"54","author":"JG Pasipanodya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0339354.ref021","author":"J Millard","year":"2023"},{"issue":"12","key":"pone.0339354.ref022","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jiac.2019.05.030","article-title":"Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study","volume":"25","author":"E Hagiwara","year":"2019","journal-title":"J Infect Chemother"},{"issue":"18","key":"pone.0339354.ref023","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2169\/internalmedicine.54.5533","article-title":"Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment","volume":"54","author":"N Horita","year":"2015","journal-title":"Intern Med"},{"issue":"10","key":"pone.0339354.ref024","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/resp.14753","article-title":"Safety of pyrazinamide in elderly patients with tuberculosis in Japan: A nationwide cohort study","volume":"29","author":"J Taniguchi","year":"2024","journal-title":"Respirology"},{"issue":"9","key":"pone.0339354.ref025","article-title":"Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study","volume":"19","author":"JY Yoon","year":"2024","journal-title":"PLoS One"},{"issue":"11","key":"pone.0339354.ref026","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/thx.49.11.1160","article-title":"Tuberculous pleural effusion: experience with six months of treatment with isoniazid and rifampicin","volume":"49","author":"C Ca\u00f1ete","year":"1994","journal-title":"Thorax"},{"issue":"6","key":"pone.0339354.ref027","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1164\/ajrccm\/145.6.1429","article-title":"Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin","volume":"145","author":"AK Dutt","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"11","key":"pone.0339354.ref028","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s10096-019-03651-7","article-title":"Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis","volume":"38","author":"JF Garc\u00eda-Rodr\u00edguez","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"pone.0339354.ref029","article-title":"Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"X-F Gao","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"12","key":"pone.0339354.ref030","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1469-0691.2009.02760.x","article-title":"Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo","volume":"15","author":"SI Zaitzeva","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0339354.ref031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/imt-2016-0079","article-title":"Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis","volume":"9","author":"U Batbold","year":"2017","journal-title":"Immunotherapy"},{"issue":"11","key":"pone.0339354.ref032","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.202401-0165OC","article-title":"Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial","volume":"210","author":"AY Xu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"pone.0339354.ref033","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200802-355OC","article-title":"Hepatotoxicity of pyrazinamide: cohort and case-control analyses","volume":"177","author":"KC Chang","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0339354.ref034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13018-021-02375-9","article-title":"Efficacy and safety of short-term chemotherapy for patients with spinal tuberculosis undergoing surgery in Chinese population: a meta-analysis","volume":"16","author":"L Lin","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"5","key":"pone.0339354.ref035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"J Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"pone.0339354.ref036","article-title":"The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis","volume":"11","author":"HW Lee","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"pone.0339354.ref037","article-title":"Rifabutin for treating pulmonary tuberculosis","volume":"2007","author":"G Davies","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pone.0339354.ref038","doi-asserted-by":"crossref","DOI":"10.18332\/pne\/186260","article-title":"Efficacy and Safety Rifapentine-Containing Regimen for Drug Sensitive Tuberculosis: Systematic Review and Meta-Analysis","volume":"37","author":"RS Deanasa","year":"2024","journal-title":"Pneumon"},{"issue":"3","key":"pone.0339354.ref039","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkt446","article-title":"Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study","volume":"69","author":"J-Y Chien","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0339354.ref040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.5588\/ijtld.11.0068","article-title":"Experience with rifabutin replacing rifampin in the treatment of tuberculosis","volume":"15","author":"DJ Horne","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pone.0339354.ref041","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw130","article-title":"Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients","volume":"3","author":"RJ Lehloenya","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"pone.0339354.ref042","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac353","article-title":"Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)","volume":"9","author":"N De Castro","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"pone.0339354.ref043","article-title":"Early discontinuation of ethambutol in pulmonary tuberculosis treatment based on results of the GenoType MTBDRplus assay: A prospective, multicenter, non-inferiority randomized trial in South Korea","volume":"63","author":"K-W Jo","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0339354.ref044","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(18)30480-8","article-title":"Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial","volume":"19","author":"J-K Lee","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pone.0339354.ref045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijid.2023.04.388","article-title":"Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis","volume":"132","author":"Y Shangguan","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pone.0339354.ref046","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1183\/09031936.00090306","article-title":"Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?","volume":"29","author":"KC Chang","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0339354.ref047","article-title":"Intermittent versus daily therapy for treating tuberculosis in children","volume":"2014","author":"A Bose","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0339354.ref048","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12664-024-01643-w","article-title":"Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis","volume":"44","author":"R Kumar","year":"2025","journal-title":"Indian J Gastroenterol"},{"key":"pone.0339354.ref049","article-title":"Adverse drug reactions and outcome of short course anti-tuberculosis drugs between single daily dose and split drug dose (BID) in pulmonary tuberculosis","volume":"95","author":"C Chuchottaworn","year":"2012","journal-title":"J Med Assoc Thai"},{"issue":"5","key":"pone.0339354.ref050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-3156.2004.01229.x","article-title":"Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach","volume":"9","author":"T Santha","year":"2004","journal-title":"Trop Med Int Health"},{"issue":"1","key":"pone.0339354.ref051","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/trstmh\/traa144","article-title":"Standard versus sequential anti-tubercular treatment in patients with tuberculous meningitis: a randomized controlled trial","volume":"115","author":"UK Misra","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"pone.0339354.ref052","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1164\/rccm.200904-0536OC","article-title":"Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion","volume":"180","author":"JL Johnson","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pone.0339354.ref053","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/cid\/civ376","article-title":"Intermittent Directly Observed Therapy for Abdominal Tuberculosis: A Multicenter Randomized Controlled Trial Comparing 6 Months Versus 9 Months of Therapy","volume":"61","author":"GK Makharia","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0339354.ref054","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejogrb.2016.05.035","article-title":"Six months versus nine months anti-tuberculous therapy for female genital tuberculosis: a randomized controlled trial","volume":"203","author":"JB Sharma","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"pone.0339354.ref055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children","volume":"386","author":"A Turkova","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0339354.ref056","article-title":"Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis","volume":"12","author":"AG Grace","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"pone.0339354.ref057","article-title":"Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis","volume":"2016","author":"CR Gallardo","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"pone.0339354.ref058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000146","article-title":"Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis","volume":"6","author":"D Menzies","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"pone.0339354.ref059","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1164\/rccm.200605-637OC","article-title":"Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis","volume":"174","author":"KC Chang","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"pone.0339354.ref060","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw566","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"P Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0339354.ref061","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1440-1746.2005.04048.x","article-title":"Monitoring and management of antituberculosis drug induced hepatotoxicity","volume":"20","author":"S Agal","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"pone.0339354.ref062","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1164\/rccm.201105-0850OC","article-title":"A comparison between two strategies for monitoring hepatic function during antituberculous therapy","volume":"185","author":"A Singanayagam","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0339354.ref063","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/1471-2458-12-454","article-title":"Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China","volume":"12","author":"S Wu","year":"2012","journal-title":"BMC Public Health"},{"key":"pone.0339354.ref064","doi-asserted-by":"crossref","first-page":"103148","DOI":"10.1016\/j.eclinm.2025.103148","article-title":"Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible tuberculosis: a systematic review","volume":"82","author":"W Burman","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"6","key":"pone.0339354.ref065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ptr.5607","article-title":"Ginger for Prevention of Antituberculosis-induced Gastrointestinal Adverse Reactions Including Hepatotoxicity: A Randomized Pilot Clinical Trial","volume":"30","author":"Z Emrani","year":"2016","journal-title":"Phytother Res"},{"key":"pone.0339354.ref066","doi-asserted-by":"crossref","first-page":"39","DOI":"10.22159\/ijpps.2021v13i4.39618","article-title":"Antiemetic activities of indonesian stingless bee propolis on emetic induced by anti-tuberculosis drugs","author":"FF Mahani","year":"2021","journal-title":"Int J Pharm Pharm Sci"},{"issue":"1","key":"pone.0339354.ref067","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1039\/C9FO01583C","article-title":"Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial","volume":"11","author":"S Lin","year":"2020","journal-title":"Food Funct"},{"key":"pone.0339354.ref068","doi-asserted-by":"crossref","first-page":"197664","DOI":"10.1016\/j.virusres.2019.197664","article-title":"Prophylactic antiviral treatment reduces the incidence of liver failure among patients coinfected with Mycobacterium tuberculosis and hepatitis B virus","volume":"270","author":"J Lian","year":"2019","journal-title":"Virus Res"},{"issue":"1","key":"pone.0339354.ref069","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11596-017-1702-3","article-title":"Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis","volume":"37","author":"C-H Zhu","year":"2017","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"4","key":"pone.0339354.ref070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/cid\/ciz241","article-title":"Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection","volume":"70","author":"GCY Lui","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0339354.ref071","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5588\/ijtld.14.0579","article-title":"Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease","volume":"19","author":"N-H Chu","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0339354.ref072","doi-asserted-by":"crossref","first-page":"876868","DOI":"10.3389\/fphar.2022.876868","article-title":"N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review","volume":"13","author":"J Sanabria-Cabrera","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0339354.ref073","article-title":"Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)","volume":"15","author":"IP Safe","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"pone.0339354.ref074","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijtb.2022.05.012","article-title":"A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life","volume":"70","author":"D Sukumaran","year":"2023","journal-title":"Indian J Tuberc"},{"issue":"7","key":"pone.0339354.ref075","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1473-3099(23)00067-1","article-title":"Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial","volume":"23","author":"GB Cross","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0339354.ref076","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5588\/ijtld.22.0548","article-title":"Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial","volume":"27","author":"OO Adewole","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"pone.0339354.ref077","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmii.2024.04.002","article-title":"The effect of statins on the risk of anti-tuberculosis drug-induced liver injury among patients with active tuberculosis: A cohort study","volume":"57","author":"C-K Huang","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"pone.0339354.ref078","first-page":"3192351","article-title":"Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"L Tao","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"pone.0339354.ref079","first-page":"206","article-title":"Effect of silymarine and Fumaria alkaloids in the prophylaxis of drug-induced liver injury during antituberculotic treatment","volume":"56","author":"D Magula","year":"1996","journal-title":"Studia Pneumologica et Phtiseologica"},{"key":"pone.0339354.ref080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/ijpvm.ijpvm_81_22","article-title":"The Effectiveness of Silymarin in the Prevention of Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized Controlled Clinical Trial","volume":"14","author":"A Talebi","year":"2023","journal-title":"Int J Prev Med"},{"key":"pone.0339354.ref081","doi-asserted-by":"crossref","first-page":"153942","DOI":"10.1016\/j.phymed.2022.153942","article-title":"Comparative effectiveness of glycyrrhizic acid preparations aimed at preventing and treating anti-tuberculosis drug-induced liver injury: A network meta-analysis of 97 randomized controlled trials","volume":"98","author":"J-Y Gong","year":"2022","journal-title":"Phytomedicine"},{"issue":"16","key":"pone.0339354.ref082","article-title":"Lactobacillus casei Alleviated the Abnormal Increase of Cholestasis-Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial","volume":"65","author":"K Xiong","year":"2021","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"pone.0339354.ref083","first-page":"431","article-title":"The Effect of acetyl-L-carnitine, Alpha-lipoic Acid, and Coenzyme Q10 Combination in Preventing Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized, Double-blind, Placebo-controlled Clinical Trial","volume":"20","author":"R Hakimizad","year":"2021","journal-title":"Iran J Pharm Res"},{"issue":"5","key":"pone.0339354.ref084","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.360","article-title":"Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients","volume":"5","author":"KI Amagon","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"pone.0339354.ref085","first-page":"175","article-title":"Efficacy of stimuliv, an indigenous compound formulation, against hepatotoxicity of antitubercular drugs--a double blind study","volume":"34","author":"SV Dange","year":"1992","journal-title":"Indian J Chest Dis Allied Sci"},{"issue":"597","key":"pone.0339354.ref086","first-page":"804","article-title":"The effects of livercare tablet [Combination of milk thistle, dandelion, barberry, tumeric (Curcumin), and artichoke] in prevention of anti-tuberculosis drugs-induced hepatotoxicity: A randomized controlled clinical trial","volume":"38","author":"M Yazdani","year":"2021","journal-title":"Journal of Isfahan Medical School"},{"issue":"1","key":"pone.0339354.ref087","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.902","article-title":"The efficacy of Jujube syrup on the prevention of drug-induced hepatotoxicity in pulmonary tuberculosis patients: A pilot randomized double-blind placebo-controlled clinical trial","volume":"10","author":"SZ Maddahi","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"pone.0339354.ref088","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jgh.12717","article-title":"Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients","volume":"30","author":"S Wu","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0339354.ref089","doi-asserted-by":"crossref","first-page":"813682","DOI":"10.3389\/fphar.2022.813682","article-title":"Effectiveness of Prophylactic Use of Hepatoprotectants for Tuberculosis Drug-Induced Liver Injury: A Population-Based Cohort Analysis Involving 6,743 Chinese Patients","volume":"13","author":"Q Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"pone.0339354.ref090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000465515","article-title":"Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?","volume":"62","author":"L Xu","year":"2017","journal-title":"Chemotherapy"},{"issue":"3","key":"pone.0339354.ref091","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.imj.2022.07.003","article-title":"Hepatoprotective drugs for prevention of liver injury resulting from anti-tuberculosis treatment: A meta-analysis of cohort studies","volume":"1","author":"D Wang","year":"2022","journal-title":"Infect Med (Beijing)"},{"issue":"1","key":"pone.0339354.ref092","doi-asserted-by":"crossref","first-page":"19880","DOI":"10.1038\/s41598-023-46565-3","article-title":"Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury","volume":"13","author":"P Akkahadsee","year":"2023","journal-title":"Sci Rep"},{"issue":"20","key":"pone.0339354.ref093","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","article-title":"Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS","volume":"379","author":"G Meintjes","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0339354.ref094","article-title":"Adjunctive steroid therapy for managing pulmonary tuberculosis","volume":"2014","author":"JA Critchley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0339354.ref095","article-title":"Corticosteroids for tuberculous pleurisy","volume":"3","author":"H Ryan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pone.0339354.ref096","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijtb.2015.05.002","article-title":"Add-on prednisolone in the management of cervical lymph node tuberculosis","volume":"63","author":"ML Bunkar","year":"2016","journal-title":"Indian J Tuberc"},{"issue":"4","key":"pone.0339354.ref097","article-title":"Corticosteroids for managing tuberculous meningitis","volume":"4","author":"K Prasad","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"pone.0339354.ref098","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa2216218","article-title":"Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults","volume":"389","author":"J Donovan","year":"2023","journal-title":"N Engl J Med"},{"key":"pone.0339354.ref099","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults","volume":"7","author":"NTH Mai","year":"2018","journal-title":"Elife"},{"key":"pone.0339354.ref100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2010.03.025","article-title":"Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial","volume":"293","author":"UK Misra","year":"2010","journal-title":"J Neurol Sci"},{"issue":"1","key":"pone.0339354.ref101","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12931-020-01488-9","article-title":"The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis","volume":"21","author":"FEA Hayford","year":"2020","journal-title":"Respir Res"},{"issue":"3","key":"pone.0339354.ref102","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s15010-024-02446-z","article-title":"The role of vitamin D in the prevention and treatment of tuberculosis: a meta-analysis of randomized controlled trials","volume":"53","author":"J Meng","year":"2025","journal-title":"Infection"},{"issue":"4","key":"pone.0339354.ref103","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ijmyco.2016.06.012","article-title":"Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy","volume":"5","author":"D Butov","year":"2016","journal-title":"Int J Mycobacteriol"},{"issue":"8","key":"pone.0339354.ref104","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/add.12148","article-title":"Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia","volume":"108","author":"S Shin","year":"2013","journal-title":"Addiction"},{"issue":"2","key":"pone.0339354.ref105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/tropicalmed7020021","article-title":"Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa","volume":"7","author":"A Reuter","year":"2022","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"pone.0339354.ref106","doi-asserted-by":"crossref","first-page":"13586","DOI":"10.1038\/s41598-024-64525-3","article-title":"Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study","volume":"14","author":"X Yanqiu","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0339354.ref107","article-title":"Prospective, open labelled, randomised, parallel group study to evaluate the efficacy and safety of metformin add-on therapy to standard ATT in newly diagnosed pulmonary tuberculosis patients","volume":"12","author":"R Kamal","year":"2022","journal-title":"International Journal of Toxicological and Pharmacological Research"},{"issue":"3","key":"pone.0339354.ref108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciab964","article-title":"Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis","volume":"75","author":"C Padmapriydarsini","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0339354.ref109","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1086\/587846","article-title":"A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis","volume":"197","author":"E Villamor","year":"2008","journal-title":"J Infect Dis"},{"key":"pone.0339354.ref110","article-title":"A PROSPECTIVE SINGLE-BLINDED STUDY ON THE SAFETY AND EFFICACY OF ZINC SUPPLEMENTATION IN PULMONARY TUBERCULOSIS","volume":"11","author":"YPK B","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"issue":"2","key":"pone.0339354.ref111","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1081\/JDI-120038490","article-title":"Salubrious effect of vitamin E supplementation on renal stone forming risk factors in urogenital tuberculosis patients","volume":"26","author":"S Srinivasan","year":"2004","journal-title":"Ren Fail"},{"issue":"3","key":"pone.0339354.ref112","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jan.13881","article-title":"Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials","volume":"75","author":"C-J Hsieh","year":"2019","journal-title":"J Adv Nurs"},{"issue":"12","key":"pone.0339354.ref113","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.23.0190","article-title":"Atorvastatin improves sputum conversion and chest X-ray severity score","volume":"27","author":"OO Adewole","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0339354.ref114","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30487-X","article-title":"Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2\u00b73 million patients with tuberculosis","volume":"7","author":"JJ Noubiap","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"1","key":"pone.0339354.ref115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13011-020-00335-w","article-title":"Prevalence and associated factors for alcohol use disorder among tuberculosis patients: a systematic review and meta-analysis study","volume":"16","author":"M Necho","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"pone.0339354.ref116","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14787210.2020.1714436","article-title":"Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis","volume":"18","author":"H Soni","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"4","key":"pone.0339354.ref117","first-page":"234","article-title":"Antituberculosis drug induced liver injury: clinical profile and outcome of various reintroduction regimens","volume":"13","author":"KR Chaitra","year":"2022","journal-title":"Journal of Cardiovascular Disease Research"},{"issue":"3","key":"pone.0339354.ref118","doi-asserted-by":"crossref","first-page":"122","DOI":"10.34172\/aim.2024.19","article-title":"Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches","volume":"27","author":"F Abbaspour","year":"2024","journal-title":"Arch Iran Med"},{"issue":"1","key":"pone.0339354.ref119","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4102\/sajhivmed.v23i1.1376","article-title":"Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort","volume":"23","author":"MS Moosa","year":"2022","journal-title":"South Afr J HIV Med"},{"issue":"1","key":"pone.0339354.ref120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5588\/ijtld.23.0038","article-title":"Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury","volume":"28","author":"Y Du","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0339354.ref121","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"JR Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"pone.0339354.ref122","first-page":"138","article-title":"Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial","volume":"12","author":"M Marjani","year":"2019","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"1","key":"pone.0339354.ref123","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/s12879-016-2000-6","article-title":"Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis","volume":"16","author":"Z Saito","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0339354.ref124","first-page":"32","article-title":"Use of the plant hepatoprotector Galstena tuberculostatics-induced hepatic lesions: experimental and clinical study","author":"O Katikova","year":"2002","journal-title":"Probl Tuberk"},{"issue":"5","key":"pone.0339354.ref125","first-page":"124","article-title":"The effect of the preparation Wobenzym on the antioxidant protection indices and on the functional-morphological properties of the erythrocytes in a toxic lesion of the liver","author":"MI Kolomoiets","year":"1999","journal-title":"Lik Sprava"},{"issue":"2","key":"pone.0339354.ref126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5958\/0976-5506.2016.00101.7","article-title":"A Study of the Oxidative Stress and the Role of Antioxidants in ATT Induced Hepatotoxicity in Tuberculosis Patients","volume":"7","author":"H Wardhan","year":"2016","journal-title":"Ind Jour of Publ Health Rese & Develop"},{"issue":"7","key":"pone.0339354.ref127","first-page":"1044","article-title":"Clinical study of deoxyribonucleotidum for adjuvant treatment of pulmonary tuberculosis with hepatic lesion","volume":"26","author":"Y Chen","year":"2006","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"15","key":"pone.0339354.ref128","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"G Meintjes","year":"2010","journal-title":"AIDS"},{"issue":"9","key":"pone.0339354.ref129","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.5588\/ijtld.11.0163","article-title":"Drug lymphocyte stimulation test is not useful for side effects of anti-tuberculosis drugs despite its timing","volume":"16","author":"S Miwa","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0339354.ref130","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1378\/chest.07-3088","article-title":"Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs","volume":"134","author":"Y Suzuki","year":"2008","journal-title":"Chest"},{"issue":"1","key":"pone.0339354.ref131","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjd.14492","article-title":"Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons","volume":"175","author":"RJ Lehloenya","year":"2016","journal-title":"Br J Dermatol"},{"issue":"12","key":"pone.0339354.ref132","first-page":"699","article-title":"Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis","volume":"75","author":"Y Kobashi","year":"2000","journal-title":"Kekkaku"},{"issue":"12","key":"pone.0339354.ref133","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"RJ Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"pone.0339354.ref134","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijtb.2021.07.018","article-title":"Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: A prospective study at a Tertiary Care Centre","volume":"69","author":"B Modi","year":"2022","journal-title":"Indian J Tuberc"},{"key":"pone.0339354.ref135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2018.01.006","article-title":"Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs","volume":"68","author":"K Siripassorn","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"3","key":"pone.0339354.ref136","first-page":"484","article-title":"Allergy to anti-tuberculosis treatment: Place of reintroduction drug test","volume":"97","author":"H Smadhi","year":"2019","journal-title":"Tunis Med"},{"issue":"3","key":"pone.0339354.ref137","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/cea.14084","article-title":"Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs","volume":"52","author":"WH Bermingham","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"pone.0339354.ref138","article-title":"Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms","volume":"9","author":"JH Oh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"39","key":"pone.0339354.ref139","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039365","article-title":"DRESS syndrome and tuberculosis: Implementation of a desensitization and re-desensitization protocol to recover antituberculosis drugs in a case series at a specialized TB Unit in Lima, Peru","volume":"103","author":"C Mor\u00e1n-Mari\u00f1os","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"pone.0339354.ref140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-4362.2001.01173-7.x","article-title":"Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization","volume":"40","author":"MM Kura","year":"2001","journal-title":"Int J Dermatol"},{"issue":"7","key":"pone.0339354.ref141","first-page":"34","article-title":"The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance","author":"MI Borisova","year":"2003","journal-title":"Probl Tuberk Bolezn Legk"},{"issue":"9","key":"pone.0339354.ref142","first-page":"45","article-title":"Adverse neurotoxic reactions of chemotherapy for tuberculosis and their treatment","author":"AV Lysov","year":"2006","journal-title":"Probl Tuberk Bolezn Legk"},{"issue":"9","key":"pone.0339354.ref143","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1255","article-title":"A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury","volume":"73","author":"MS Moosa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pone.0339354.ref144","article-title":"Monitoring and management strategies for MDR\/RR-TB treatment","author":"World Health Organization","year":"2025"},{"issue":"3","key":"pone.0339354.ref145","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/499244","article-title":"Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection","volume":"42","author":"K Ijaz","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0339354.ref146","article-title":"Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea","volume":"10","author":"J Lim","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"pone.0339354.ref147","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.202101-0117OC","article-title":"Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials","volume":"204","author":"MZ Imperial","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0339354.ref148","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5588\/ijtld.18.0324","article-title":"NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis","volume":"23","author":"M Richardson","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pone.0339354.ref149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"M Utsunomiya","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"pone.0339354.ref150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00042560-200008010-00007","article-title":"Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268","volume":"24","author":"MF Para","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"pone.0339354.ref151","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend","volume":"159","author":"DE Griffith","year":"2021","journal-title":"Chest"},{"issue":"2","key":"pone.0339354.ref152","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"J Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"pone.0339354.ref153","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","article-title":"Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting","volume":"131","author":"TJ Gan","year":"2020","journal-title":"Anesth Analg"},{"issue":"10","key":"pone.0339354.ref154","first-page":"2879","article-title":"Effect of netupitant, a highly selective NK\u2081 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives","volume":"21","author":"S Calcagnile","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"pone.0339354.ref155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0009-9236(99)70130-X","article-title":"The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron","volume":"65","author":"K Villikka","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"pone.0339354.ref156","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40261-019-00775-8","article-title":"A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects","volume":"39","author":"L Sun","year":"2019","journal-title":"Clin Drug Investig"},{"key":"pone.0339354.ref157","article-title":"Adverse events of first-line therapy for pediatric tuberculosis: A systematic review and meta-analysis","author":"M Prodanuk","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T18:35:17Z","timestamp":1766774117000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339354"}},"subtitle":[],"editor":[{"given":"Selvakumar","family":"Subbian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":157,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339354","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}